More Evidence That Titles Do Not an Expert Make: Statins

I hate reading stuff like this because after all I started out wanting to make some good pills for peoples' health. More often than I like to read, these companies pawn useless stuff that causes another disease. It's cut and paste from http://www.hoptechno.com/statinsheets.htm

If the authors contact me, I'll gladly remove it but I can simply link to it. Perhaps the intentions were good in the beginning, but the disease misunderstood, and the outcome terrible, all the while the corporate fat cats lined their pockets at the expense of peoples' arteries. To me, that is more morbid and disturbing than a horror movie but I am sure plenty of people will come to the aid of the statin camp. The next post I have will be even more mind boggling.

"Cancer, Longevity and Statins


Do statins cause cancer or affect longevity?
Editor's note: The following are a sample of results of a search on the safety of statins (Cholesterol lowering drugs; e.g. Lipitor, Mevacor, Pravachol, Zocor).

It appears that:

1. there is a danger that statins cause cancer in humans
2. death rates in the population have not been reduced as a result of statin use
3. prescribing sheets show that statins cause liver cancer in animals.

Cancer: Source - Journal of the American Medical Association (JAMA) January 1996 The following is an extract.

Carcinogenicity of lipid-lowering drugs.

Newman TB, Hulley SB.

Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, USA.

OBJECTIVE--To review the findings and implications of studies of rodent carcinogenicity of lipid-lowering drugs. DATA SOURCES--Summaries of carcinogenicity studies published in the 1992 and 1994 Physicians' Desk Reference (PDR), additional information obtained from the US Food and Drug Administration, and published articles identified by computer searching, bibliographies, and consultation with experts. STUDY SAMPLE--We tabulated rodent carcinogenicity data from the 1994 PDR for all drugs listed as "hypolipidemics." For comparison, we selected a stratified random sample of antihypertensive drugs. We also reviewed methods and interpretation of carcinogenicity studies in rodents and results of clinical trials in humans. DATA SYNTHESIS--All members of the two most popular classes of lipid-lowering drugs (the fibrates and the statins) cause cancer in rodents, in some cases at levels of animal exposure close to those prescribed to humans. In contrast, few of the antihypertensive drugs have been found to be carcinogenic in rodents. Evidence of carcinogenicity of lipid-lowering drugs from clinical trials in humans is inconclusive because of inconsistent results and insufficient duration of follow-up.

CONCLUSIONS--Extrapolation of this evidence of carcinogenesis from rodents to humans is an uncertain process. Longer-term clinical trials and careful postmarketing surveillance during the next several decades are needed to determine whether cholesterol-lowering drugs cause cancer in humans. In the meantime, the results of experiments in animals and humans suggest that lipid-lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short-term risk of coronary heart disease.

Death Rate. Source: http://www.drugintel.com/drugs/statins/statins_critical_review.htm - This link was taken down.

Besides cancer, the other side effects of statins listed were incomplete, and should have included constipation, myalgia, myopathy, polyneuropathy, liver and kidney damage, congestive heart failure and amnesia. Side-effects are usually said to affect 2-6% of patients. In fact, a recent meta-analysis noted side-effects in 20% of patients above the placebo rate (65% vs. 45%), and no change whatever in the all-cause death rate for atorvastatin (Lipitor). [8] The PROSPER trial on pravastatin (Pravachol) showed no change in the all-cause death rate, and increased cancer and stroke rates. [9] Statins are commonly used at a dose to lower TC to <160 mg/dL, a level noted in the report of a NHLBI conference to be associated with higher cancer rates.[10]

Footnotes:
[8] Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of Atorvastatin Derived from Analysis of 44 Completed Trials in 9,416 Patients. Am J Cardiol 2003;92:670-6.
[9] Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360(9346):1623-30.
[10] Jacobs D, Blackburn H, Higgins M et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation 1992:86:1046-60.

Death Rate: Source: Archives of Internal Medicine Vol. 153 No. 9, May 10, 1993 Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data http://archinte.ama-assn.org/cgi/content/abstract/153/9/1065

Conclusion: Physicians should be cautious about initiating cholesterol-lowering treatment in men and women above 65 to 70 years of age. Only randomized clinical trials in older people can settle the debate over the efficacy and cost-effectiveness of lipid-lowering interventions for reducing mortality and morbidity in this population.

The relationship between total cholesterol level and all-cause mortality was positive (ie, higher cholesterol level associated with higher mortality) at age 40 years, negative at age 80 years, and negligible at ages 50 to 70 years. The relationship with CHD mortality was significantly positive at ages 40, 50, and 60 years but attenuated with age until the relationship was positive, but not significant, at age 70 years and negative, but not significant, at age 80 years. Results for the relationship between low-density lipoprotein cholesterol and high-density lipoprotein cholesterol and mortality help explain these findings. Non-CHD mortality was significantly negatively related to cholesterol level for ages 50 years and above. [Ed: - low cholesterol = higher non-chd mortality; high cholesterol = lower; CHD = Coronary Heart Disease]

Prescribing sheets published by manufacturers of statin drugs (Oct 2005): [ALL of them mentioned liver cancer as a side effect]

Lipitor: In a 2-year carcinogenicity study in rats at dose levels of 10, 30, and 100 mg/kg/day, 2 rare tumors were found in muscle in high-dose females: in one, there was a rhabdomyosarcoma and, in another, there was a fibrosarcoma. This dose represents a plasma AUC (0-24) value of approximately 16 times the mean human plasma drug exposure after an 80 mg oral dose. A 2-year carcinogenicity study in mice given 100, 200, or 400 mg/kg/day resulted in a significant increase in liver adenomas in high-dose males and liver carcinomas in highdose females. These findings occurred at plasma AUC (0-24) values of approximately 6 times the mean human plasma drug exposure after an 80 mg oral dose.

Mevacor: In a 24-month carcinogenicity study in rats, there was a positive dose response relationship for hepatocellular carcinogenicity in males at drug exposures between 2-7 times that of human exposure at 80 mg/day (doses in rats were 5, 30 and 180 mg/kg/day).

Pravachol: Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year study in rats fed pravastatin at doses of 10, 30, or 100 mg/kg body weight, there was an increased incidence of hepatocellular carcinomas in males at the highest dose (p<0.01). These effects in rats were observed at approximately 12 times the human dose (HD) of 80 mg, based on body surface area mg/m2 and at approximately 4 times the human dose, based on AUC. In a 2-year study in mice fed pravastatin at doses of 250 and 500 mg/kg/day, there was an increased incidence of hepatocellular carcinomas in males and females at both 250 and 500 mg/kg/day (p<0.0001). At these doses, lung adenomas in females were increased (p=0.013). These effects in mice were observed at approximately 15 times (250 mg/kg/day) and 23 times (500 mg/kg/day) the human dose of 80 mg, based on AUC. In another 2-year study in mice with doses up to 100 mg/kg/day (producing drug exposures approximately 2 times the human dose of 80 mg, based on AUC), there were no drug-induced tumors. No evidence of mutagenicity was observed in vitro, with or without rat-liver metabolic activation, in the following studies: microbial mutagen tests, using mutant strains of Salmonella typhimurium or Escherichia coli ; a forward mutation assay in L5178Y TK +/- mouse lymphoma cells; a chromosomal aberration test in hamster cells; and a gene conversion assay using Saccharomyces cerevisiae. In addition, there was no evidence of mutagenicity in either a dominant lethal test in mice or a micronucleus test in mice.

Zocor: In a 72-week carcinogenicity study, mice were administered daily doses of simvastatin of 25, 100, and 400 mg/kg body weight, which resulted in mean plasma drug levels approximately 1, 4, and 8 times higher than the mean human plasma drug level, respectively (as total inhibitory activity based on AUC) after an 80-mg oral dose. Liver carcinomas were significantly increased in high-dose females and midand high-dose males with a maximum incidence of 90% in males. The incidence of adenomas of the liver was significantly increased in mid- and high-dose females. Drug treatment also significantly increased the incidence of lung adenomas in mid- and high-dose males and females. Adenomas of the Harderian gland (a gland of the eye of rodents) were significantly higher in high-dose mice than in controls. No evidence of a tumorigenic effect was observed at 25 mg/kg/day. In a separate 92-week carcinogenicity study in mice at doses up to 25 mg/kg/day, no evidence of a tumorigenic effect was observed (mean plasma drug levels were 1 times higher than humans given 80 mg simvastatin as measured by AUC). In a two-year study in rats at 25 mg/kg/day, there was a statistically significant increase in the incidence of thyroid follicular adenomas in female rats exposed to approximately 11 times higher levels of simvastatin than in humans given 80 mg simvastatin (as measured by AUC). A second two-year rat carcinogenicity study with doses of 50 and 100 mg/kg/day produced hepatocellular adenomas and carcinomas (in female rats at both doses and in males at 100 mg/kg/day). Thyroid follicular cell adenomas were increased in males and females at both doses; thyroid follicular cell carcinomas were increased in females at 100 mg/kg/day. The increased incidence of thyroid neoplasms appears to be consistent with findings from other HMG-CoA reductase inhibitors. These treatment levels represented plasma drug levels (AUC) of approximately 7 and 15 times (males) and 22 and 25 times (females) the mean human plasma drug exposure after an 80 milligram daily dose. No evidence of mutagenicity was observed in a microbial mutagenicity (Ames) test with or without rat or mouse liver metabolic activation. In addition, no evidence of damage to genetic material was noted in ZOCOR® (simvastatin) 9556649 14 an in vitro alkaline elution assay using rat hepatocytes, a V-79 mammalian cell forward mutation study, an in vitro chromosome aberration study in CHO cells, or an in vivo chromosomal aberration assay in mouse bone marrow.

Crestor: (Jan 2006) In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage, the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Increased incidence of polyps was not seen at lower doses. In a 107-week carcinogenicity study in mice given 10, 60, 200 mg/kg/day by oral gavage, an increased incidence of hepatocellular adenoma/carcinoma was observed at 200 mg/kg/day at systemic exposures 20 times human exposure at 40 mg/day based on AUC. An increased incidence of hepatocellular tumors was not seen at lower doses. Rosuvastatin was not mutagenic or clastogenic with or without me

Effect of Different Antilipidemic Agents and Diets on Mortality

A Systematic Review

Marco Studer, MD; Matthias Briel, MD; Bernd Leimenstoll, MD; Tracy R. Glass, MSc; Heiner C. Bucher, MD, MPH

Arch Intern Med. 2005;165:725-730.

Background Guidelines for the prevention and treatment of hyperlipidemia are often based on trials using combined clinical end points. Mortality data are the most reliable data to assess efficacy of interventions. We aimed to assess efficacy and safety of different lipid-lowering interventions based on mortality data.

Methods We conducted a systematic search of randomized controlled trials published up to June 2003, comparing any lipid-lowering intervention with placebo or usual diet with respect to mortality. Outcome measures were mortality from all, cardiac, and noncardiovascular causes.

Results A total of 97 studies met eligibility criteria, with 137 140 individuals in intervention and 138 976 individuals in control groups. Compared with control groups, risk ratios for overall mortality were 0.87 for statins (95% confidence interval [CI], 0.81-0.94), 1.00 for fibrates (95% CI, 0.91-1.11), 0.84 for resins (95% CI, 0.66-1.08), 0.96 for niacin (95% CI, 0.86-1.08), 0.77 for n-3 fatty acids (95% CI, 0.63-0.94), and 0.97 for diet (95% CI, 0.91-1.04). Compared with control groups, risk ratios for cardiac mortality indicated benefit from statins (0.78; 95% CI, 0.72-0.84), resins (0.70; 95% CI, 0.50-0.99) and n-3 fatty acids (0.68; 95% CI, 0.52-0.90). Risk ratios for noncardiovascular mortality of any intervention indicated no association when compared with control groups, with the exception of fibrates (risk ratio, 1.13; 95% CI, 1.01-1.27).

Conclusions Statins and n-3 fatty acids are the most favorable lipid-lowering interventions with reduced risks of overall and cardiac mortality. Any potential reduction in cardiac mortality from fibrates is offset by an increased risk of death from noncardiovascular causes.

Author Affiliations: Basel Institute for Clinical Epidemiology (Drs Studer, Briel, and Bucher and Ms Glass) and Department of Internal Medicine (Drs Studer and Leimenstoll), University Hospital Basel, Basel, Switzerland. (http://archinte.ama-assn.org/cgi/content/abstract/165/7/725)
An article on 2/19/8 from Wall Street Journal begins: COGNITIVE SIDE EFFECTS like memory loss and fuzzy thinking aren't listed on the patient information sheet for Lipitor, the popular cholesterol-lowering drug. But some doctors are voicing concerns that in a small portion of patients, statins like Lipitor may be helping hearts but hurting minds.

"This drug makes women stupid," Orli Etingin, vice chairman of medicine at New York Presbyterian Hospital, declared at a recent luncheon discussion sponsored by Project A.L.S. to raise awareness of gender issues and the brain. Dr. Etingin, who is also founder and director of the Iris Cantor Women's Health Center in New York, told of a typical patient in her 40s, unable to concentrate or recall words. Tests found nothing amiss, but when the woman stopped taking Lipitor, the symptoms vanished. When she resumed taking Lipitor, they returned.

"I've seen this in maybe two dozen patients," Dr. Etingin said later, adding that they did better on other statins. "This is just observational, of course. We really need more studies, particularly on cognitive effects and women."


Comments from visitors:

I was prescribed Mevacor about 20 years ago and became so incapacitated with muscle pain I had to seek medical attention. I was taken off the Mevacor and put on another, I can't remember which at this time, but over 20 years, I have been prescribed every statin available, the last was Crestor, which I took for 3 days and then had a heart attack. Before that, however, I was prescribed Tricor and my kidneys stopped after the 3rd dose and I became extremely ill. Then came the Crestor and the heart attack. For twenty years I have suffered from these muscular pains and when I expressed thoughts that they came from the cholesteral drug I was taking, they just gave me another. After my heart surgery and diagnosis of LAD, my surgeon, Dr. Rosenthal, told me to never take statins again; however, my cardiologist wanted me to try again and I refused and left the office no longer his patient. It has been two years since I have taken a cholesteral lowering drug and my cholesteral is now the lowest it has been since I first began statin therapy. (4/2/06)
My husband died last August 2005 of advanced liver cancer (hepatocellular carcinoma). He tested negative for hepatitis and cirrhosis as the common causes of liver cancer. Nothing ever was said about the lovastatin (mevacor) that he was on since 2003 when he had a mild heart attack. A friend (non-M.D.)mentioned the statin probably caused the cancer. Now, reading your research study results about mevacor and seeing the exact cancer that my husband had, I am wondering if it WAS the mevacor that caused the HCC. WHY was he not more closely monitored? I assume he wasn't since, by the time it was accidentally discovered, his cancer was too advanced to do anything. What can we do as laymen to protect ourselves if our physicians are not protecting us? His cardiologist, by the way, attended him even after his cancer was diagnosed and did not stop his medications. His primary doctor prescribed pain killers for 3 months for his pain and did not order any tests. Another doctor (when his primary was not available) ordered the CT-scan and that's when his cancer was discovered. He died 3 months later. We are with Kaiser - however, is the problem still there regardless of whether you are with an HMO or not? I really would like to know what our options are; what we can do, if anything. (5/5/06)

Article Index

Planning a Wedding? Click Here. | Manage your neighborhood Book Club. | Chinese Medicine and Art. | Census data about you. | US Directory of Vendors

©1986-2009 Hopkins Technology, LLC "